Kornimate/medical-research-clean huggingface dataset:
diastolic deceleration area in late-onset fgr

Conditions: Hypoxia; Anemia

Summary: dda is a new doppler parameter aiming to assess fetal well-being in-utero. late-onset fgr is a specific subgroup of fetuses where the clinical application of this doppler modality could play an essential role in detecting hypoxia, anemia, and other adverse neonatal outcomes.


Eligibility criteria:
inclusion criteria: * absence of fetal abnormalities and/or genetic conditions; * single pregnancy; * fetal growth restriction (fgr) \< 10%, according to the intergrowth 21st nomograms, appearing after 32nd week of gestation exclusion criteria: * documented fetal abnormalities and/or genetic conditions in the course of the pregnancy; * multiple pregnancy; * absence of fetal growth restriction (fgr) \< 10%, according to the intergrowth 21st nomograms after 32nd week of gestation
clinical investigation plan for iqon spectral ct at utrecht medical center (umc)

Conditions: Artery; Deformity; Coronary (Acquired)

Summary: the ct examination on iqon spectral ct would be a standard of care ct performed as per the clinical indication. the conventional ct images generated by the scanner will be used for clinical purposes as routinely practiced. and therefore, the primary study aim is to assess the impact of iqon spectral ct scanner and applications on the clinical workflow of the site as well as the diagnostic confidence levels of the physicians reading the ct cases. in addition to the aim mentioned above, the investigators would like to develop recommendations for the clinical application of the spectral images in routine use. such recommendations could include optimization of scanning protocols, optimization of reconstruction parameters; evaluate the utility of iodine maps and other supported materials.

the study aim is to assess the added diagnostic value and impact on workflow of philips iqon spectral computed tomography. the iqon spectral ct generates two result types: * conventional ct images which are equivalent to images produced by the commercially available brilliance ict scanner * spectral ct images which are unique to this product. the ct examination would be a standard of care ct performed as per the clinical indication. in addition to the aim mentioned above, the investigators would like to develop recommendations for the clinical application of the spectral images in routine use. such recommendations could include optimization of scanning parameters, optimization of reconstruction parameters to utilize the capabilities of the iqon system etc. the clinical system includes: * the iqon spectral ct scanner * spectral diagnostic suite (philips intellispace portal): includes 5 applications. spectral enhanced ct viewer, spectral enhanced advanced analysis, spectral enhanced comprehensive cardiac analysis, spectral enhanced tumor tracking, spectral magic glass on pacs. the testing will be conducted under this project plan. this is a single center research study that is expected to be conducted over a one year period.

Eligibility criteria:
inclusion criteria: * subjects clinically indicated to have a ct scan as part of their routine, standard medical care. subjects must be capable of providing informed consent for the retrospective use and analysis of the iqon spectral ct data for the research study. exclusion criteria: * subjects that are not clinically indicated to have a ct scan as part of their routine, standard medical care. subjects that are not capable of providing informed consent for the retrospective use and analysis of the iqon spectral ct data for the research study.

Keywords: ct spectral images
mastery learning versus time-based education: skill acquisition and retention of basic life support in laypeople

Conditions: Basic Life Support; Cardiac Arrest

Summary: background: in cardiac arrest survival rates dramatically increase when bystanders are present and initiate basic life support (bls). however, even though serious efforts have been made, skill retention after a traditional time-based bls course for laypeople remains suboptimal. in contrast, a mastery learning-based educational approach was shown to be efficacious and might be promising even for laypersons. therefore the investigators aim to evaluate the impact of a mastery learning-based bls course on skills retention of bls in laypeople. methods: forty laypeople without previous bls experiences will be randomized into the traditional time-based bls course group (control - tb group) or mastery learning-based group (intervention - ml group). both groups will receive bls training consisting of 6 successive stations including diagnosis of cardiac arrest, chest compression, ventilation, one-rescuer bls, two-rescuer bls and aed use. in the ml group, subjects will deliberately practice and receive feedback at each station until a pre-set target level is reached. subjects will be allowed to proceed to the next station only when they achieve the required target level of performance. in contrast, participants of the tb group will be taught the same 6 stations in two hours, according to standard american heart association bls criteria. all subjects will have an assessment of knowledge and skills immediately after teaching (immediate post-test) and at four months (retention post-test). implications: previous research has shown that mastery learning-based education improves learners' procedural skill performance. the investigators study will determine the impact of a mastery learning-based bls course on skill retention in laypeople.


Eligibility criteria:
inclusion criteria: * university students in ottawa exclusion criteria: * students of the faculty of medicine * previous basic life support training certificate
a study on the possible health effects of lean fish and fatty fish intake in overweight or obese adults

Conditions: Overweight; Obesity

Summary: the potential health effects of high intake of lean or fatty fish will be investigated in overweight or obese adults. participants consume 750g/week of fillets of fish for 8 weeks. hypothesis: high intake of fatty or lean fish will beneficially affect glucose regulation and the immune system.


Eligibility criteria:
inclusion criteria: * bmi ≥27 kg/m2 * fasting blood glucose ≤7.0 mmol/l exclusion criteria: * pregnancy * incompatibility with fish consumption (allergies, intolerance and/or dislike) * diagnosed diabetes mellitus, heart disease or gastrointestinal diseases * use of medications affecting lipid metabolism or glucose homeostasis * use of anti-inflammatory medications * use of supplements containing long chain n-3 fatty acids * intentional weight loss * and large fluctuation in body weight (\>3 kg) over the previous two months
effects of spirulina on cardiac functions in children with beta thalassemia major

Conditions: Beta Thalassemia

Summary: the aim of this study is to evaluate the cardioprotective effect of spirulina in children with beta thalassemia.

the aim of this study is to evaluate the cardioprotective effect of spirulina in children with beta thalassemia. this study will be carried on thirty children with beta thalassemia major from those attending the hematology unit of pediatric department at tanta university hospital, and another thirty healthy children of matched age and sex will be enrolled as controls. all studied children will be subjected to careful history taking and through clinical examination. laboratory investigations will be done including complete blood count, hemoglobin electrophoresis, serum ferritin, liver and kidney functions, and troponin-1 plasma level. echocardiographic assessment of the cardiac functions will be done for all patients. source data will be the patients medical records. oral spirulina will be given for studied patients for 3 months, and clinical examination, laboratory investigations and cardiac functions will be assessed at the time of inclusion in the study, and again after 3 months of regular spirulina supplementation. an informed consent will be obtained from parents of all included subjects. the results of this study will be tabulated and statistically analyzed using statistical package for the social sciences (spss).

Eligibility criteria:
inclusion criteria: * children suffering from beta thalassemia major with age range from 4-18 years exclusion criteria: * children with congenital heart diseases children with rheumatic heart diseases presence of heart failure children with coronary arterial disease children with cardiomyopathy
subcutaneous treatment with icatibant for acute attacks of hereditary angioedema

Conditions: Angioedema

Summary: the purpose of this study is to assess the efficacy and safety of icatibant, a bradykinin antagonist in the treatment of acute cutaneous and/or abdominal attacks in patients with hereditary angioedema (hae).

this phase ii/iii study consisted of two parts: a controlled phase and an open label extension(ole) phase. the controlled phase describes the double blind part of the study and was intended to evaluate the efficacy of icatibant in decreasing the time to onset of symptom relief compared with placebo for the first treated cutaneous and/or abdominal attack in randomised patients. patients experienced a laryngeal attack were not randomised, but treated with open label icatibant according to the controlled phase procedures and assessments. the outcome of this group was to be reported descriptively. after treatment of the first attack in the controlled phase, the patients were eligible to enter the ole phase. in the ole phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the end of the study.the ole phase became a modified open label extension where all 56 patients who had been randomised and the last randomised patient had concluded the double-blind phase. the modified open label extension period permitted treatment for patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the double blind phase was still ongoing.

Eligibility criteria:
inclusion criteria: * age above 18 years; * documented diagnosis of hae type i or ii (confirmed complement 1 esterase inhibitor \[c1-inh\] deficiency); * current edema be in the cutaneous, abdominal and/or laryngeal areas; * current edema be moderate to severe according to the investigator's symptom score. exclusion criteria: * diagnosis of angioedema other than hae, for example, acquired angioedema (aae); * participation in a clinical trial of another investigational medicinal product (imp) within the past month; * treatment with any pain medication since onset of the current edema attack; * treatment with replacement therapy, including c1-inh products (e.g. human c1-inh preparations), less than 3 days from onset of the current edema attack; * treatment with ace inhibitors (e.g. lotensin, prinivil, accupril); * evidence of severe, symptomatic coronary artery disease based on medical history or screening examination; * serious concomitant illnesses that the physician considers to be a contraindication for participation in the trial; * pregnancy and/or breast-feeding.

Keywords: hereditary angioedema c1 inhibitor deficiency hae icatibant bradykinin antagonist acute attack subcutaneous
enhancing motivation to quit smoking in smokers with serious mental illness

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this project will assess the utility of a brief motivational intervention to engage smokers with schizophrenia in treatment for tobacco dependence treatment. it is hypothesized that a brief motivational intervention will be more effective in engaging smokers with schizophrenia to tobacco dependence treatment than an educational intervention. the educational intervention will increase the likelihood to reducing cigarette intake and/or attending tobacco dependence treatment by teaching subjects about the negative effects of smoking and the success of tobacco dependence treatment. the motivational intervention will increase the likelihood to reducing cigarette intake and/or attending tobacco dependence treatment by increasing subjects' motivation to change by presenting objective and personalized information regarding their smoking behaviors in a non-judgmental and supportive manner.

see brief summary above.

Eligibility criteria:
inclusion criteria: * current smokers must be over the age of 18, * must have a diagnosis of schizophrenia or schizoaffective disorder * must smoke at least 10 cigarettes per day * must be capable of giving informed consent as measured by folstein mini mental status exam of at least 22 exclusion criteria: •those unable to give informed consent.
durg coated balloon angioplasty in infrapopliteal lesions

Conditions: Arteriosclerosis; Peripheral Artery Disease; Chronic Limb Threatening Ischemia

Summary: this study is a multicenter observational study designed to evaluate the the effectiveness and safety of drug-coated balloon (dcb) angioplasty for below the knee arterial lesions in patients critical with limb threatening ischemia (clti).

patients with critical limb ischemia (rutherford category 4-5) and significant infrapopliteal lesions appropriate for angioplasty will be enrolled in this study. subjects will be treated with the acoart drug coated balloon, then follow-up will be conducted at 1, 3, 6, 12 months after index procedure. data on wound, ischemia, foot infection (wifi) calcifications, clinical improvements, wound healing, freedom form target- lesion revascularization, patency of the target lesion and major adverse events will be collected.

Eligibility criteria:
inclusion criteria: 1. rutherford grade 4-5. 2. patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up. 3. single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the infrapopliteal arteries \>20 mm. lesions should not extend beyond the ankle joint. 4. successful wire crossing of the lesion. after the pre-dilation of the ordinary balloon, the angiography showed that there was continuous blood flow. 5. at least one of the infrapopliteal arteries received a drug-coated balloon. 6. for patients with aortoiliac artery disease and femoral-popliteal artery disease, after intravascular reconstruction, blood flow can be recanalized, and there is no residual stenosis of more than 50%. 7. in patients with lower extremity arterial thrombosis, after mechanical thrombectomy, percutaneous catheter thrombolysis, and thrombus removal, patients receiving blew the knee arterial drug balloon intervention. 8. patients who have received dcb intervention for both lower limbs can be enrolled in the group according to the intracavitary treatment time. 9. life expectancy\> 24 months. exclusion criteria: 1. blood flow was not successfully reestablished. 2. patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment. 3. patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc. 4. patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months. 5. pregnant and lactating women. 6. patients with berg's disease. 7. patients requiring major amputation based on preoperative evaluation of limb infection or severe ischemia

Keywords: drug-coated balloon angioplasty below the knee
management strategy for acute cholecystitis in the digestive surgery department and geriatric unit in subjects over and under 75 years

Conditions: Acute Cholecystitis

Summary: the management of these often frail elderly patients, with more comorbidities and declining functional capacities, is more complex and justifies a specific, tailored approach. age is also associated with an increasing prevalence of gallstones. the disadvantages of "cold" surgery (longer hospital stay, higher cost, risk of disease recurrence in the interim, difficult surgery with more scar tissue due to repeated inflammation) have to be weighed against the high operative risk in the case of emergency surgery, leading to strict criteria for early cholecystectomy. these criteria are rarely met in geriatric patients, who thus enter a hospital cycle whose impact on morbidity and mortality, as well as on loss of autonomy, has been demonstrated in this population. what's more, the deteriorating general condition of frail elderly patients means that a number of them end up being definitively rejected for surgery, despite an initial strategy of cold cholecystectomy.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * diagnosis of acute cholecystitis. * hospitalization in the digestive surgery department and geriatric perioperative unit of nîmes university hospital. exclusion criteria: * patients under 18 years of age. * opposition of the patient to his inclusion in the study after sending the letter of information and non-opposition.
improving quality of life of fibromyalgia patients

Conditions: Fibromyalgia

Summary: comparison of two treatments of fibromyalgia; the qol score should improve rather and, twelve months after the end of the program, remain higher in "plurifocal educational group" than in control group

comparing two forms of non-drug treatment of fibromyalgia: "information" (an information group session on the fibromyalgia management modalities) versus "plurifocal educational program " (intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy).

Eligibility criteria:
inclusion criteria: * fibromyalgia patients according to the criteria of the american college of rheumatology defined by: * diffuse pain evolving for over three months * pain on palpation of at least 11 of the 18 sites listed * age between 18 and 65 * fiq score higher than 35/100 at inclusion * ability to respond to questionnaires * monitoring possibility for at least a year * affiliation to the french health system (social security) exclusion criteria: * association with chronic pain from other sources which can interfere with fibromyalgia assessment * inability to follow the full educational program * previous participation in an educational program of same nature * psychological disorder (personality disorder or behaviour, schizophrenia), preventing participation in the program group

Keywords: cognitive behavioral long-term study education
study of efficacy, safety and effect on radiographic progression of brodalumab in subjects with psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: the primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.

the primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. the key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16 and week 24. the safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Eligibility criteria:
inclusion criteria: * subject has a diagnosis of psoriatic arthritis (by the classification of psoriatic arthritis criteria (caspar), with ≥ 3 tender and ≥ 3 swollen joints (excluding the distal interphalangeal joints)). * subjects must have at least 1 psoriatic skin lesion as well as either ≥ 1 erosion on a centrally read radiograph or an elevated crp. exclusion criteria: * subject has known history of active tuberculosis. * subject has a planned surgical intervention between baseline and the week 52 evaluation. * subject has an active infection or history of infections. * subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, diabetes, anemia) considered by the investigator to be clinically significant and uncontrolled. * subject has any concurrent medical condition or electrocardiogram (ecg) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject. * subject has severe depression measured by personal health questionnaire depression scale (phq-8) or suicidal ideation/behavior as measured by and columbia suicide severity rating scale (e-cssrs) * subject has a history or evidence of psychiatric disorder or substance abuse considered by the investigator to pose a risk to subject safety

Keywords: psoriatic arthritis brodalumab amg 827
guselkumab for hidradenitis suppurativa, a mode of action study.

Conditions: Hidradenitis Suppurativa

Summary: this is a multicenter open-label mode of action study. twenty patients with moderate to severe hidradenitis suppurativa will be treated with guselkumab 200 mg q4w subcutaneously. main objectie is to investigate changes in inflammatory pathways induced by il-23p19 blockade with guselkumab, in hs lesional skin. the total duration of the treatment period per subject is 16 weeks.


Eligibility criteria:
key inclusion criteria: * moderate to severe hs * treatment history of at least one systemic anti-inﬂammatory / immunosuppressive agent; * hs diagnosis of at least 1 year; * minimum of two anatomical locations with hs lesions * minimum of 4 active abscesses and/or inflammatory nodules (an). key exclusion criteria: * contra-indication for guselkumab; * previous use of guselkumab; * use of treatment with biologics or any immunosuppressives for hs in the last 3 months prior to randomization; * presence of other uncontrolled major disease; * pregnant or lactating women